Bioinformatics-assisted anti-HIV therapy

Nature Reviews Microbiology

Volumn 4, Issue 10, 2006, Pages 790-797

  Lengauer, Thomas ^a   Sing, Tobias ^a  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BIOINFORMATICS; CLINICAL TRIAL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; DRUG TREATMENT FAILURE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INTERNET; MEDICAL DECISION MAKING; MICROBIAL DIVERSITY; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; SOFTWARE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748848279     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1477     Document Type: Article

References (55)

1. UNAIDS. AIDS epidemic update: December 2005. UNAIDS web site [online], (2005).
2. Sing, T. & Däumer, M. in Antiretroviral Resistance in Clinical Practice (ed. Geretti, A. M.) 43-56 (Mediscript, London, 2005).
3. Hastie, T., Tibshirani, R. & Friedman, J. The Elements of Statistical Learning (Springer, New York, 2001).
4. Reeves, J. D. & Piefer, A. J. Emerging drug targets for antiretroviral therapy. Drugs 65, 1747-1766 (2005).
5. Vermeiren, H. et al. Application of multiple linear regression modelling to the quantitative prediction of HIV-1 drug susceptibility phenotype from viral genotype. Antivir. Ther. 9, S122 (2004).
6. Wang, K., Jenwitheesuk, E., Samudrala, R. & Mittler, J. E. Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance. Antivir. Ther. 9, 343-352 (2004).
7. Sevin, A. D. et al. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J. Infect. Dis. 182, 59-67 (2000).
8. Foulkes, A. S. & De Gruttola, V. Characterizing the relationship between HIV-1 genotype and phenotype: Prediction-based classification. Biometrics 58, 145-156 (2002).
9. Foulkes, A. S. & De Gruttola, V. Characterizing classes of antiretroviral drugs by genotype. Stat. Med. 22, 2637-2655 (2003).
10. Wang, D. & Larder, B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J. Infect. Dis. 188, 653-660 (2003).
11. Potter, R. B. & Draghici, S. A SOFM approach to predicting HIV drug resistance. Pac. Symp. Biocomput. 77-87 (2002).
12. Beerenwinkel, N. et al. Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype. Proc. Natl Acad. Sci. USA 99, 8271-8276 (2002).
13. Beerenwinkel, N. et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 31, 3850-3855 (2003).
14. Larder, B. et al. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Antivir. Ther. 4, S59 (1999).
15. DiRienzo, A. G., De Gruttola, V., Larder, B. & Hertogs, K. Non-parametric methods to predict HIV drug susceptibility phenotype from genotype. Stat. Med. 22, 2785-2798 (2003).
16. Rabinowitz, M. et al. Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization. Bioinformatics 22, 541-549 (2006).
17. Van Houtte, M. et al. The VirtualPhenotype analysis of an HIV-1 genotype provides a more accurate prediction of drug susceptibility than a single phenotype measurement. Proc. 13th Int. Symp. HIV Emerging Infect. Dis. (2004).
18. Jenwitheesuk, E., Wang, K., Mittler, J. E. & Samudrala, R. Improved accuracy of HIV-1 genotypic susceptibility interpretation using a consensus approach. AIDS 18, 1858-1859 (2004).
19. Wang, K., Samudrala, R. & Mittler, J. E. HIV-1 genotypic drug-resistance interpretation algorithms need to include hypersusceptibility-associated mutations. J. Infect. Dis. 190, 2055-2056 (2004).
20. Jenwitheesuk, E. & Samudrala, R. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antivir. Ther. 10, 157-166 (2005).
21. Draghici, S. & Potter, R. B. Predicting HIV drug resistance with neural networks. Bioinformatics 19, 98-107 (2003).
22. Shenderovich, M. D., Kagan, R. M., Heseltine, P. N. & Ramnarayan, K. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. Protein Sci. 12, 1706-1718 (2003).
23. Jenwitheesuk, E. & Samudrala, R. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Struct. Biol. 3, Article 2 (2003).
24. Maggio, E. T., Shenderovich, M., Kagan, R., Goddette, D. & Ramnarayan, K. Structural pharmacogenomics, drug resistance and the design of anti-infective superdrugs. Drug Discov. Today 7, 1214-1220 (2002).
25. Cao, Z. W. et al. Computer prediction of drug resistance mutations in proteins. Drug Discov. Today 10, 521-529 (2005).
26. Jenwitheesuk, E., Wang, K., Mittler, J. E. & Samudrala, R. PIRSpred: A web server for reliable HIV-1 protein-inhibitor resistance/ susceptibility prediction. Trends Microbiol. 13, 150-151 (2005).
27. Beerenwinkel, N. et al. Geno2pheno: Interpreting genotypic HIV drug resistance tests. IEEE Intelligent Syst. 16, 35-41 (2001).
28. Brun-Vezinet, F. et al., Clinically validated genotype analysis: Guiding principles and statistical concerns. Antivir. Ther. 9, 465-478 (2004).
29. Flandre, P. et al. Comparison of tests and procedures to build clinically relevant genotypic scores: Application to the Jaguar study. Antivir. Ther. 10, 479-487 (2005).
30. Clavel, F., Soriano, V. & Zolopa, A. R. in HIV infection 101-107 (Bash Medical Publishing, Paris, 2004).
31. Swanstrom, R. et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J. Infect. Dis. 190, 886-893 (2004).
32. Beerenwinkel, N. et al. Methods for optimizing antiviral combination therapies. Bioinformatics 19 (Suppl. 1), i16-i25 (2003).
33. Bacheler, L. et al. Estimation of phenotypic clinical cutoffs for VirtualPhenotype through meta analyses of clinical trial and cohort data. Antivir. Ther. 9, S154 (2004).
34. Nowak, M. A. & May, R. M. Virus Dynamics (Oxford Univ. Press, Oxford, 2000).
35. Wodarz, D. & Nowak, M. A. Mathematical models of HIV pathogenesis and treatment. Bioessays 24, 1178-1187 (2002).
36. Csajka, C. & Verotta, D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J. Pharmacokinet. Pharmacodyn. 33, 227-279 (2006).
37. Prosperi, M. et al. 'Common law' applied to treatment decisions for drug resistant HIV. Antivir. Ther. 10, S62 (2005).
38. DeGruttola, V. et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5, 41-48 (2000).
39. Savenkov, I. et al. HAART outcome prediction using statistical learning methods. Antivir. Ther. 10, S60 (2005).
40. Lathrop, R. & Pazzani, M. Combinatorial optimization in rapidly mutating drug-resistant viruses. J. Comb. Optim. 3, 301-320 (1999).
41. Beerenwinkel, N. et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J. Infect. Dis. 191, 1953-1960 (2005).
42. Foulkes, A. S. & De Gruttola, V. Characterizing the progression of viral mutations over time. J. Am. Stat. Assoc. 98, 859-867 (2003).
43. Beerenwinkel, N. & Drton, M. A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. Biostatistics (in the press).
44. Sloot, P. M., Boukhanovsky, A. V., Keulen, W., Tirado-Ramos, A. & Boucher, C. A. A Grid-based HIV expert system. J. Clin. Monit. Comput. 19, 263-278 (2005).
45. Segal, M. R., Barbour, J. D. & Grant, R. M. Relating HIV-1 sequence variation to replication capacity via trees and forests. Stat. Appl. Genet. Mol. Biol. 3, Article 2 (2004).
46. Birkner, M. D., Sinisi, S. E. & Van der Laan, M. Multiple testing and data adaptive regression: An application to HIV-1 sequence data. Stat. Appl. Genet. Mol. Biol. 4, Article 8 (2005).
47. Larder, B. et al. Treatment history and adherence information significantly improves prediction of virological response by neural networks. Antivir. Ther. 10, S57 (2005).
48. Marcelin, A. G. et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 49, 1720-1726 (2005).
49. Rendon, A. et al. Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med. 6, 360-365 (2005).
50. Marcelin, A. G. et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47, 594-600 (2003).
51. Wahl, L. M. & Nowak, M. A. Adherence and drug resistance: Predictions for therapy outcome. Proc. Biol. Sci. 267, 835-843 (2000).
52. Jiang, H. et al. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J. Infect. Dis. 188, 1001-1008 (2003).
53. Johnson, V. A. et al. Update of the drug resistance mutations in HIV-1: fall 2005. Top. HIV Med. 13, 125-131 (2005).
54. Roomp, K. et al. in Data Integration in the Life Sciences (eds Leser, U., Naumann, F. & Eckman, B. A.) 185-194 (Springer, New York, 2006).
55. Cozzi-Lepri, A. et al. Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir. Ther. 10, 791-802 (2005).